VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	9/22/2010 4:14:34 PM
	of 1972

this: xml.10kwizard.com and this: "Vical weakness a buying opportunity, says Rodman & Renshaw Rodman & Renshaw views the sell-off in Vical (VICL) shares from the setback for NV1FGF as a strong buying opportunity. The firm sees catalysts in the second half of 2010 and 2011 to drive shareholder value and notes it was not modeling for any potential milestones from Sanofi-aventis (SNY) in connection with NV1FGF."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next